Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,484.82
(
-1.62%
)
US TECH 100
22,988.80
(
-2.23%
)
Dow Jones
45,952.06
(
-1.03%
)
Brent Oil
102.17
(
3.44%
)
Bitcoin
68,372.04
(
-4.11%
)
News Focus
News Focus
Post# of 257293
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122814
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Biowatch post# 1922

Thursday, 04/22/2004 9:10:45 AM

Thursday, April 22, 2004 9:10:45 AM

Post# of 257293
>> Genaera will begin additional mid-stage, or Phase II, trials during the current quarter and Phase III trials early next year while the earlier study is still underway. <<

Overlapping phase-2 and phase-3 trials --this is a very positive development!

This compressed timeline should significantly increase the attractiveness of the AMD program to prospective partners.

I can’t wait to see the trial-design details and the list of clinical sites.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today